{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:39:15Z","timestamp":1789155555995,"version":"build-2803163510"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Centre Egypt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, accounting for 60\u201380% of dementia cases. It is characterized by gradual cognitive decline, neuronal loss, and pathological hallmarks, including amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles of hyperphosphorylated tau protein. This review provides a comprehensive overview of AD, emphasizing its etiology, molecular mechanisms, risk factors, and current therapeutic strategies. Multiple hypotheses, including the amyloid cascade, tau, cholinergic, vascular, and neuroinflammatory theories, are discussed to elucidate disease pathogenesis. Genetic mutations in the APP, PSEN1, and PSEN2 genes, along with environmental and lifestyle factors, are shown to influence disease onset and progression. The treatment landscape is rapidly evolving from traditional symptomatic therapies, such as cholinesterase inhibitors and NMDA receptor antagonists, to emerging disease-modifying agents targeting amyloid, tau, and neuroinflammation. Novel approaches, including glutaminyl cyclase inhibitors, PDE inhibitors, serotonin receptor modulators, and metabolic therapies, offer new hope for altering disease progression. Non-pharmacological interventions, such as diet, exercise, and lifestyle modifications, also play a key preventive role. Despite ongoing challenges, advancements in biomarker research, neuroimaging, and precision medicine are improving early detection and individualized treatment strategies. Continuous innovation in pharmacotherapy and diagnostics promises to reshape the future of AD management and enhance patients\u2019 quality of life. The current review focuses on bridging the gaps in AD\u2019s current and emerging Therapies.<\/jats:p>","DOI":"10.1007\/s10787-026-02151-3","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:03:14Z","timestamp":1774249394000},"page":"2219-2241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bridging the gaps in alzheimer\u2019s disease: a comprehensive review of current and emerging therapies"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-350X","authenticated-orcid":false,"given":"Rasha E.","family":"Mostafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7679-5968","authenticated-orcid":false,"given":"Gihan F.","family":"Asaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"7","key":"2151_CR50","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.4239\/wjd.v15.i7.1430","volume":"15","author":"MMI Abdalla","year":"2024","unstructured":"Abdalla MMI (2024) Insulin resistance as the molecular link between diabetes and alzheimer\u2019s disease. World J Diabetes 15(7):1430","journal-title":"World J Diabetes"},{"issue":"2","key":"2151_CR137","first-page":"295","volume":"11","author":"EAM AbdAlla","year":"2021","unstructured":"AbdAlla EAM, Aly SE, Saleh YEA, Beshay MSK, Hathout AS (2021) BAY 73-6691 alters neuron plasticity and phosphorylation of Tau through regulation of Cyclic Guanosine monophosphate\/Protein kinase G\/Cyclic adenosine monophosphate response Element-Binding protein pathway. Toxicol Appl Pharmacol 11(2):295\u2013301","journal-title":"Toxicol Appl Pharmacol"},{"issue":"16","key":"2151_CR69","doi-asserted-by":"publisher","first-page":"11057","DOI":"10.1039\/D3RA08333K","volume":"14","author":"AE Abdallah","year":"2024","unstructured":"Abdallah AE (2024) Review on anti-alzheimer drug development: approaches, challenges and perspectives. RSC Adv 14(16):11057\u201311088","journal-title":"RSC Adv"},{"issue":"1","key":"2151_CR167","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13195-022-01055-y","volume":"14","author":"C Abdelnour","year":"2022","unstructured":"Abdelnour C, Agosta F, Bozzali M, Foug\u00e8re B, Iwata A, Nilforooshan R et al (2022) Perspectives and challenges in patient stratification in alzheimer\u2019s disease. Alzheimers Res Ther 14(1):112","journal-title":"Alzheimers Res Ther"},{"key":"2151_CR144","doi-asserted-by":"publisher","first-page":"1429211","DOI":"10.3389\/fnagi.2024.1429211","volume":"16","author":"AS Abdul Manap","year":"2024","unstructured":"Abdul Manap AS, Almadodi R, Sultana S, Sebastian MG, Kavani KS, Lyenouq VE et al (2024) Alzheimer\u2019s disease: a review on the current trends of the effective diagnosis and therapeutics. Front Aging Neurosci 16:1429211","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"2151_CR103","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/biof.2039","volume":"50","author":"T Abdul-Rahman","year":"2024","unstructured":"Abdul-Rahman T, Awuah WA, Mikhailova T, Kalmanovich J, Mehta A, Ng JC et al (2024) Antioxidant, anti-inflammatory and epigenetic potential of Curcumin in alzheimer\u2019s disease. BioFactors 50(4):693\u2013708","journal-title":"BioFactors"},{"issue":"11","key":"2151_CR136","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1007\/s10072-024-07583-9","volume":"45","author":"ME Abouelmagd","year":"2024","unstructured":"Abouelmagd ME, Abdelmeseh M, Elrosasy A, Saad YH, Alnajjar AZ, Eid M et al (2024) Phosphodiesterase-5 inhibitors use and the risk of alzheimer\u2019s disease: a systematic review and meta-analysis. Neurol Sci 45(11):5261\u20135270","journal-title":"Neurol Sci"},{"issue":"6","key":"2151_CR68","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.neuron.2009.12.016","volume":"64","author":"A Aguzzi","year":"2009","unstructured":"Aguzzi A, Rajendran L (2009) The transcellular spread of cytosolic Amyloids, Prions, and prionoids. Neuron 64(6):783\u2013790","journal-title":"Neuron"},{"issue":"1","key":"2151_CR142","doi-asserted-by":"publisher","first-page":"e13129","DOI":"10.1111\/bpa.13129","volume":"33","author":"AB Ali","year":"2023","unstructured":"Ali AB, Islam A, Constanti A (2023) The fate of interneurons, GABAA receptor sub-types and perineuronal Nets in alzheimer\u2019s disease. Brain Pathol 33(1):e13129","journal-title":"Brain Pathol"},{"issue":"5","key":"2151_CR116","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2174\/092986708783503203","volume":"15","author":"F Amenta","year":"2008","unstructured":"Amenta F, Tayebati S (2008) Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Curr Med Chem 15(5):488\u2013498","journal-title":"Curr Med Chem"},{"issue":"1","key":"2151_CR180","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1038\/s41467-021-23507-z","volume":"12","author":"L Amin","year":"2021","unstructured":"Amin L, Harris DA (2021) A\u03b2 receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun 12(1):3451","journal-title":"Nat Commun"},{"issue":"4","key":"2151_CR46","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/ijms24043754","volume":"24","author":"J Andrade-Guerrero","year":"2023","unstructured":"Andrade-Guerrero J, Santiago-Balmaseda A, Jeronimo-Aguilar P, Vargas-Rodr\u00edguez I, Cadena-Su\u00e1rez AR, S\u00e1nchez-Garibay C et al (2023) Alzheimer\u2019s Disease: An Updated Overview of Its Genetics. Int J Mol Sci 24(4):3754","journal-title":"Int J Mol Sci"},{"key":"2151_CR44","doi-asserted-by":"crossref","unstructured":"Andrews SJ, Renton AE, Fulton-Howard B, Podlesny-Drabiniok A, Marcora E, Goate AM (2023) The complex genetic architecture of alzheimer\u2019s disease: novel insights and future directions. eBioMedicine. ;90","DOI":"10.1016\/j.ebiom.2023.104511"},{"issue":"2","key":"2151_CR168","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/biomedicines11020335","volume":"11","author":"A Arafah","year":"2023","unstructured":"Arafah A, Khatoon S, Rasool I, Khan A, Rather MA, Abujabal KA et al (2023) The future of precision medicine in the cure of alzheimer\u2019s disease. Biomedicines 11(2):335","journal-title":"Biomedicines"},{"issue":"1","key":"2151_CR184","first-page":"1","volume":"16","author":"M Arastoo","year":"2024","unstructured":"Arastoo M, Penny LK, Lofthouse R, Abdallah A, Abrahamsson A, Marini P et al (2024) High-affinity antibodies specific to the core region of the Tau protein exhibit diagnostic and therapeutic potential for alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 16(1):1\u201320","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"1","key":"2151_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/alz.12192","volume":"17","author":"AFT Arnsten","year":"2021","unstructured":"Arnsten AFT, Datta D, Del Tredici K, Braak H, Hypothesis (2021) Tau pathology is an initiating factor in sporadic alzheimer\u2019s disease. Alzheimer\u2019s Dement 17(1):115\u2013124","journal-title":"Alzheimer\u2019s Dement"},{"issue":"8","key":"2151_CR23","doi-asserted-by":"publisher","first-page":"e70404","DOI":"10.1002\/alz.70404","volume":"21","author":"AFT Del Arnsten","year":"2025","unstructured":"Arnsten AFT, Del Tredici K, Barth\u00e9lemy NR, Gabitto M, van Dyck CH, Lein E et al (2025) An integrated view of the relationships between amyloid, tau, and inflammatory pathophysiology in alzheimer\u2019s disease. Alzheimers Dement 21(8):e70404","journal-title":"Alzheimers Dement"},{"issue":"13","key":"2151_CR58","doi-asserted-by":"publisher","first-page":"e34092","DOI":"10.1016\/j.heliyon.2024.e34092","volume":"10","author":"S Ashique","year":"2024","unstructured":"Ashique S, Mohanto S, Ahmed MG, Mishra N, Garg A, Chellappan DK et al (2024) Gut-brain axis: A cutting-edge approach to target neurological disorders and potential synbiotic application. Heliyon 10(13):e34092","journal-title":"Heliyon"},{"issue":"7","key":"2151_CR97","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1007\/s11033-021-06512-9","volume":"48","author":"T Athar","year":"2021","unstructured":"Athar T, Al Balushi K, Khan SA (2021) Recent advances on drug development and emerging therapeutic agents for alzheimer\u2019s disease. Mol Biol Rep 48(7):5629\u20135645","journal-title":"Mol Biol Rep"},{"issue":"6","key":"2151_CR110","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1111\/bcp.15206","volume":"88","author":"AC Baakman","year":"2022","unstructured":"Baakman AC, Gavan C, van Doeselaar L, de Kam M, Broekhuizen K, Bajenaru O et al (2022) Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with alzheimer\u2019s disease. Br J Clin Pharmacol 88(6):2814\u20132829","journal-title":"Br J Clin Pharmacol"},{"key":"2151_CR129","doi-asserted-by":"publisher","first-page":"174310","DOI":"10.1016\/j.ejphar.2021.174310","volume":"908","author":"P Babaei","year":"2021","unstructured":"Babaei P (2021) NMDA and AMPA receptors dysregulation in alzheimer\u2019s disease. Eur J Pharmacol 908:174310","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2151_CR154","doi-asserted-by":"publisher","first-page":"718","DOI":"10.14283\/jpad.2023.114","volume":"10","author":"M Barbera","year":"2023","unstructured":"Barbera M, Perera D, Matton A, Mangialasche F, Rosenberg A, Middleton L et al (2023) Multimodal precision Prevention - A new direction in alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis 10(4):718\u2013728","journal-title":"J Prev Alzheimer\u2019s Dis"},{"issue":"2","key":"2151_CR120","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1007\/s12035-024-04388-x","volume":"62","author":"HS Basir","year":"2025","unstructured":"Basir HS, Mirazi N, Komaki A, Mohamadpour B, Hosseini A (2025) Selegiline improves cognitive impairment in the rat model of alzheimer\u2019s disease. Mol Neurobiol 62(2):2548\u20132560","journal-title":"Mol Neurobiol"},{"key":"2151_CR14","doi-asserted-by":"publisher","first-page":"1459224","DOI":"10.3389\/fnagi.2024.1459224","volume":"16","author":"C Behl","year":"2024","unstructured":"Behl C (2024) In the amyloid-cascade-hypothesis still remains a working hypothesis, no less but certainly no more. Front Aging Neurosci 16:1459224","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"2151_CR117","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2174\/1570159X19666210517114016","volume":"20","author":"S Bhatia","year":"2022","unstructured":"Bhatia S, Rawal R, Sharma P, Singh T, Singh M, Singh V (2022) Mitochondrial dysfunction in alzheimer\u2019s disease: opportunities for drug development. Curr Neuropharmacol 20(4):675\u2013692","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"2151_CR165","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","volume":"139","author":"T Bieber","year":"2017","unstructured":"Bieber T, D\u2019Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Sch\u00e4ppi G et al (2017) Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol 139(4):S58\u201364","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2151_CR67","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrn3887","volume":"16","author":"J Brettschneider","year":"2015","unstructured":"Brettschneider J, Del Tredici K, Lee VMY, Trojanowski JQ (2015) Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 16(2):109","journal-title":"Nat Rev Neurosci"},{"key":"2151_CR164","doi-asserted-by":"crossref","unstructured":"Brockmann R, Nixon J, Love BL, Yunusa I (2023) Impacts of FDA approval and medicare restriction on antiamyloid therapies for alzheimer\u2019s disease: patient outcomes, healthcare costs, and drug development. Lancet Reg Heal - Am. ;20","DOI":"10.1016\/j.lana.2023.100467"},{"issue":"1","key":"2151_CR39","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/cells9010150","volume":"9","author":"Q Cai","year":"2020","unstructured":"Cai Q, Jeong YY (2020) Mitophagy in alzheimer\u2019s disease and other Age-Related neurodegenerative diseases. Cells 9(1):150","journal-title":"Cells"},{"key":"2151_CR94","doi-asserted-by":"publisher","first-page":"1465871","DOI":"10.3389\/fnagi.2024.1465871","volume":"16","author":"W Cai","year":"2025","unstructured":"Cai W, Zhang H, Wu Y, Yao Y, Zhang J (2025) Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with alzheimer\u2019s disease: a systematic review and network meta-analysis of randomized controlled trials. Front Aging Neurosci 16:1465871","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"2151_CR147","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1038\/s41380-023-02140-w","volume":"28","author":"G Carello-Collar","year":"2023","unstructured":"Carello-Collar G, Bellaver B, Ferreira PCL, Ferrari-Souza JP, Ramos VG, Therriault J et al (2023) The GABAergic system in alzheimer\u2019s disease: a systematic review with meta-analysis. Mol Psychiatry 28(12):5025\u20135036","journal-title":"Mol Psychiatry"},{"key":"2151_CR12","doi-asserted-by":"crossref","unstructured":"Castellani RJ, Jamshidi P, Plascencia-Villa G, Perry G (2024) The amyloid cascade hypothesis: A conclusion in search of support. Am J Pathol","DOI":"10.1016\/j.ajpath.2024.10.014"},{"issue":"7","key":"2151_CR131","doi-asserted-by":"publisher","first-page":"7","DOI":"10.53879\/id.61.07.14382","volume":"61","author":"P Chandra","year":"2024","unstructured":"Chandra P, Sharma H (2024) Phosphodiesterase inhibitors for treatment, of alzheimer\u2019s disease. Indian Drugs 61(7):7\u201322","journal-title":"Indian Drugs"},{"issue":"6","key":"2151_CR35","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/molecules27061816","volume":"27","author":"ZR Chen","year":"2022","unstructured":"Chen ZR, Huang JB, Yang SL, Hong FF (2022a) Role of cholinergic signaling in alzheimer\u2019s disease. Molecules 27(6):1816","journal-title":"Molecules"},{"issue":"6","key":"2151_CR106","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/molecules27061816","volume":"27","author":"ZR Chen","year":"2022","unstructured":"Chen ZR, Huang JB, Yang SL, Hong FF (2022b) Role of cholinergic signaling in alzheimer\u2019s disease. Molecules 27(6):1816","journal-title":"Molecules"},{"key":"2151_CR139","doi-asserted-by":"publisher","first-page":"1209863","DOI":"10.3389\/fnagi.2023.1209863","volume":"15","author":"D Chen","year":"2023","unstructured":"Chen D, Chen Q, Qin X, Tong P, Peng L, Zhang T et al (2023) Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of alzheimer\u2019s disease. Front Aging Neurosci 15:1209863","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"2151_CR172","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/eb-2018-102890","volume":"21","author":"A Chinner","year":"2018","unstructured":"Chinner A, Blane J, Lancaster C, Hinds C, Koychev I (2018) Digital technologies for the assessment of cognition: a clinical review. Evid Based Ment Health 21(2):67","journal-title":"Evid Based Ment Health"},{"issue":"1","key":"2151_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00401-019-02087-9","volume":"139","author":"M Colin","year":"2019","unstructured":"Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade JP et al (2019) From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol 139(1):3","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2151_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.biopsych.2017.10.007","volume":"83","author":"C Condello","year":"2017","unstructured":"Condello C, Yuan P, Grutzendler J (2017) Microglia-mediated neuroprotection, TREM2 and alzheimer\u2019s disease: evidence from optical imaging. Biol Psychiatry 83(4):377","journal-title":"Biol Psychiatry"},{"issue":"12","key":"2151_CR90","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM (2023) Tau-targeting therapies for alzheimer disease: current status and future directions. Nat Rev Neurol 19(12):715\u2013736","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"2151_CR76","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","volume":"72","author":"V Coric","year":"2015","unstructured":"Coric V, Salloway S, Van Dyck CH, Dubois B, Andreasen N, Brody M et al (2015) Targeting prodromal alzheimer disease with avagacestat: A randomized clinical trial. JAMA Neurol 72(11):1324\u20131333","journal-title":"JAMA Neurol"},{"issue":"1","key":"2151_CR186","first-page":"1","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK et al (2025) Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 17(1):1\u201312","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"2151_CR38","doi-asserted-by":"publisher","first-page":"102713","DOI":"10.1016\/j.arr.2025.102713","volume":"107","author":"MCB D\u2019Alessandro","year":"2025","unstructured":"D\u2019Alessandro MCB, Kanaan S, Geller M, Pratic\u00f2 D, Daher JPL (2025) Mitochondrial dysfunction in alzheimer\u2019s disease. Ageing Res Rev 107:102713","journal-title":"Ageing Res Rev"},{"issue":"1","key":"2151_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/156720512799015037","volume":"9","author":"M de la Monte","year":"2012","unstructured":"de la Monte M (2012) Brain insulin resistance and deficiency as therapeutic targets in alzheimer\u2019s disease. Curr Alzheimer Res 9(1):35","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"2151_CR48","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","volume":"88","author":"SM De La Monte","year":"2013","unstructured":"De La Monte SM, Tong M (2013) Brain metabolic dysfunction at the core of alzheimer\u2019s disease. Biochem Pharmacol 88(4):548","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2151_CR123","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/biof.1714","volume":"47","author":"A Delgado","year":"2021","unstructured":"Delgado A, Cholevas C, Theoharides TC (2021) Neuroinflammation in alzheimer\u2019s disease and beneficial action of Luteolin. BioFactors 47(2):207\u2013217","journal-title":"BioFactors"},{"issue":"2","key":"2151_CR89","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/biomedicines13020279","volume":"13","author":"D Dias","year":"2025","unstructured":"Dias D, Socodato R (2025) Beyond amyloid and tau: the critical role of microglia in alzheimer\u2019s disease therapeutics. Biomedicines 13(2):279","journal-title":"Biomedicines"},{"issue":"10","key":"2151_CR83","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/14737175.2025.2546868","volume":"25","author":"R Dodel","year":"2025","unstructured":"Dodel R, Fr\u00f6lich L (2025) Donanemab for alzheimer\u2019s disease: from preclinical research to the clinical application. Expert Rev Neurother 25(10):1151\u20131163","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"2151_CR21","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/ijms26031004","volume":"26","author":"J Dominguez-Gortaire","year":"2025","unstructured":"Dominguez-Gortaire J, Ruiz A, Porto-Pazos AB, Rodriguez-Yanez S, Cedron F (2025) Alzheimer\u2019s disease: exploring pathophysiological hypotheses and the role of machine learning in drug discovery. Int J Mol Sci 26(3):1004","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2151_CR183","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D et al (2024) Alzheimer disease is a clinical-biological construct: an IWG recommendation. JAMA Neurol 81(12):1304","journal-title":"JAMA Neurol"},{"issue":"18","key":"2151_CR71","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B et al (2018) Randomized trial of verubecestat for Mild-to-Moderate alzheimer\u2019s disease. N Engl J Med 378(18):1691\u20131703","journal-title":"N Engl J Med"},{"key":"2151_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.trsl.2022.12.003","volume":"254","author":"LB Eisenmenger","year":"2022","unstructured":"Eisenmenger LB, Peret A, Famakin BM, Spahic A, Roberts GS, Bockholt JH et al (2022) Vascular contributions to alzheimer\u2019s disease. Transl Res 254:41","journal-title":"Transl Res"},{"issue":"8","key":"2151_CR145","first-page":"1266","volume":"60","author":"NC Eryilmaz","year":"2024","unstructured":"Eryilmaz NC, Arslan M, Kucuk A, Tuna AT, Guney S, Kaplanoglu GT et al (2024) Evaluation of the effects of repetitive anaesthesia administration on the brain tissues and cognitive functions of rats with experimental alzheimer\u2019s disease. Med (Kaunas) 60(8):1266","journal-title":"Med (Kaunas)"},{"key":"2151_CR158","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2147\/NDT.S264910","volume":"17","author":"T Fulop","year":"2021","unstructured":"Fulop T, Tripathi S, Rodrigues S, Desroches M, Bunt T, Eiser A et al (2021) Targeting impaired antimicrobial immunity in the brain for the treatment of alzheimer\u2019s disease. Neuropsychiatr Dis Treat 17:1311\u20131339","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"2151_CR43","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1002\/alz.14121","volume":"20","author":"YJ Ge","year":"2024","unstructured":"Ge YJ, Chen SD, Wu BS, Zhang YR, Wang J, He XY et al (2024) Genome-wide meta-analysis identifies ancestry-specific loci for alzheimer\u2019s disease. Alzheimer\u2019s Dement 20(9):6243\u20136256","journal-title":"Alzheimer\u2019s Dement"},{"issue":"12","key":"2151_CR13","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1002\/alz.13136","volume":"19","author":"C Gericke","year":"2023","unstructured":"Gericke C, Kirabali T, Flury R, Mallone A, Rickenbach C, Kulic L et al (2023) Early \u03b2-amyloid accumulation in the brain is associated with peripheral T cell alterations. Alzheimer\u2019s Dement 19(12):5642\u20135662","journal-title":"Alzheimer\u2019s Dement"},{"issue":"6","key":"2151_CR153","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s11011-023-01225-3","volume":"38","author":"G Goodarzi","year":"2023","unstructured":"Goodarzi G, Tehrani SS, Fana SE, Moradi-Sardareh H, Panahi G, Maniati M et al (2023) Crosstalk between alzheimer\u2019s disease and diabetes: a focus on anti-diabetic drugs. Metab Brain Dis 38(6):1769\u20131800","journal-title":"Metab Brain Dis"},{"key":"2151_CR3","doi-asserted-by":"publisher","first-page":"102161","DOI":"10.1016\/j.arr.2023.102161","volume":"93","author":"A Granzotto","year":"2024","unstructured":"Granzotto A, Sensi SL (2024) Once upon a time, the amyloid cascade hypothesis. Ageing Res Rev 93:102161","journal-title":"Ageing Res Rev"},{"issue":"9","key":"2151_CR160","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.3390\/ijms23094962","volume":"23","author":"S Gunes","year":"2022","unstructured":"Gunes S, Aizawa Y, Sugashi T, Sugimoto M, Rodrigues PP (2022) Biomarkers for alzheimer\u2019s disease in the current state: A narrative review. Int J Mol Sci 23(9):4962","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2151_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo H, Callaway JB, Ting JPY, Inflammasomes (2015) Mechanism of Action, role in Disease, and therapeutics. Nat Med 21(7):677","journal-title":"Nat Med"},{"issue":"5","key":"2151_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo T, Noble W, Hanger DP (2017) Roles of Tau protein in health and disease. Acta Neuropathol 133(5):665","journal-title":"Acta Neuropathol"},{"issue":"202223","key":"2151_CR17","first-page":"NA","volume":"211","author":"Y Guo","year":"2022","unstructured":"Guo Y, Li S, Zeng L-H, Tan J (2022) Tau-targeting therapy in alzheimer\u2019s disease: critical advances and future opportunities. Ageing Neur Dis 211(202223):NA\u2013NA","journal-title":"Ageing Neur Dis"},{"issue":"Suppl 2","key":"2151_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/jnc.14052","volume":"142","author":"J Haam","year":"2017","unstructured":"Haam J, Yakel JL (2017) Cholinergic modulation of the hippocampal region and memory function. J Neurochem 142(Suppl 2):111","journal-title":"J Neurochem"},{"issue":"8","key":"2151_CR113","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1176\/appi.ajp.2015.15010093","volume":"173","author":"GM Haig","year":"2016","unstructured":"Haig GM, Bain EE, Robieson WZ, Baker JD, Othman AA (2016) A randomized trial to assess the efficacy and safety of ABT-126, a selective \u03b17 nicotinic acetylcholine receptor Agonist, in the treatment of cognitive impairment in schizophrenia. Am J Psychiatry 173(8):827\u2013835","journal-title":"Am J Psychiatry"},{"issue":"3","key":"2151_CR181","first-page":"e70139","volume":"17","author":"ME Hodsdon","year":"2025","unstructured":"Hodsdon ME, Abel A, Chambers A, Lu M, Morris A, Pontecorvo MJ et al (2025) Clinical validation of the Lilly SP-X P\u2010tau217 assay: performance in underrepresented cohorts. Alzheimer\u2019s dement diagnosis. Assess Dis Monit 17(3):e70139","journal-title":"Assess Dis Monit"},{"issue":"1","key":"2151_CR45","first-page":"e12155","volume":"13","author":"J Van Hoogmartens","year":"2021","unstructured":"Hoogmartens J, Cacace R, Van Broeckhoven C (2021) Insight into the genetic etiology of alzheimer\u2019s disease: A comprehensive review of the role of rare variants. Alzheimer\u2019s Dement Diagnosis Assess Dis Monit 13(1):e12155","journal-title":"Alzheimer\u2019s Dement Diagnosis Assess Dis Monit"},{"key":"2151_CR79","doi-asserted-by":"publisher","first-page":"1522058","DOI":"10.3389\/fphar.2025.1522058","volume":"16","author":"J Huang","year":"2025","unstructured":"Huang J, Long X, Chen C (2025) A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system. Front Pharmacol 16:1522058","journal-title":"Front Pharmacol"},{"key":"2151_CR55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neurobiolaging.2021.07.014","volume":"107","author":"A Ionescu-Tucker","year":"2021","unstructured":"Ionescu-Tucker A, Cotman CW (2021) Emerging roles of oxidative stress in brain aging and alzheimer\u2019s disease. Neurobiol Aging 107:86\u201395","journal-title":"Neurobiol Aging"},{"issue":"8","key":"2151_CR182","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al (2024) Revised criteria for diagnosis and staging of alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimers Dement 20(8):5143\u20135169","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2151_CR91","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12935-023-03193-1","volume":"24","author":"H Johnson","year":"2024","unstructured":"Johnson H, Narayan S, Sharma AK (2024) Altering phosphorylation in cancer through PP2A modifiers. Cancer Cell Int 24(1):11","journal-title":"Cancer Cell Int"},{"issue":"12","key":"2151_CR96","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.3390\/ijms22126637","volume":"22","author":"E Kadu\u0161evi\u010dius","year":"2021","unstructured":"Kadu\u0161evi\u010dius E (2021) Novel applications of nsaids: insight and future perspectives in Cardiovascular, Neurodegenerative, diabetes and cancer disease therapy. Int J Mol Sci 22(12):6637","journal-title":"Int J Mol Sci"},{"key":"2151_CR166","unstructured":"Kane M (2024) Lecanemab therapy and APOE genotype. Med Genet Summ"},{"issue":"6","key":"2151_CR25","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.4049\/jimmunol.1400716","volume":"193","author":"A Katsumoto","year":"2014","unstructured":"Katsumoto A, Lu H, Miranda AS, Ransohoff RM (2014) Ontogeny and functions of CNS macrophages. J Immunol 193(6):2615","journal-title":"J Immunol"},{"key":"2151_CR122","doi-asserted-by":"publisher","first-page":"148905","DOI":"10.1016\/j.brainres.2024.148905","volume":"1834","author":"K Kaur","year":"2024","unstructured":"Kaur K, Kulkarni YA, Wairkar S (2024) Exploring the potential of Quercetin in alzheimer\u2019s disease: Pharmacodynamics, Pharmacokinetics, and nanodelivery systems. Brain Res 1834:148905","journal-title":"Brain Res"},{"issue":"10","key":"2151_CR1","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1093\/brain\/awad159","volume":"146","author":"KP Kepp","year":"2023","unstructured":"Kepp KP, Robakis NK, H\u00f8ilund-Carlsen PF, Sensi SL, Vissel B (2023) The amyloid cascade hypothesis: an updated critical review. Brain 146(10):3969\u20133990","journal-title":"Brain"},{"issue":"7","key":"2151_CR128","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s11064-022-03598-w","volume":"47","author":"H Khan","year":"2022","unstructured":"Khan H, Singh TG, Dahiya RS, Abdel-Daim MM (2022) \u03b1-Lipoic Acid, an organosulfur biomolecule a novel therapeutic agent for neurodegenerative disorders: an mechanistic perspective. Neurochem Res 47(7):1853\u20131864","journal-title":"Neurochem Res"},{"issue":"2","key":"2151_CR78","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1358\/dof.2019.44.2.2895649","volume":"44","author":"G Khanna","year":"2024","unstructured":"Khanna G, Bhandari R, Kuhad A, Kuhad A (2024) Aducanumab Drugs Future 44(2):115\u2013121","journal-title":"Aducanumab Drugs Future"},{"key":"2151_CR52","doi-asserted-by":"publisher","first-page":"815063","DOI":"10.3389\/fendo.2022.815063","volume":"13","author":"JH Kim","year":"2022","unstructured":"Kim JH, Lee HS, Kim YH, Kwon MJ, Kim JH, Min CY et al (2022) The association between thyroid diseases and alzheimer\u2019s disease in a National health screening cohort in Korea. Front Endocrinol (Lausanne) 13:815063","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2151_CR32","doi-asserted-by":"publisher","first-page":"686","DOI":"10.14283\/jpad.2023.109","volume":"10","author":"M Kiraly","year":"2023","unstructured":"Kiraly M, Foss JF, Giordano T, Neuroinflammation (2023) Its role in alzheimer\u2019s disease and therapeutic strategies. J Prev Alzheimer\u2019s Dis 10(4):686\u2013698","journal-title":"J Prev Alzheimer\u2019s Dis"},{"issue":"7","key":"2151_CR188","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/alz.12123","volume":"16","author":"M Kivipelto","year":"2020","unstructured":"Kivipelto M, Mangialasche F, Snyder HM, Allegri R, Andrieu S, Arai H et al (2020) World-Wide FINGERS network: A global approach to risk reduction and prevention of dementia. Alzheimers Dement 16(7):1078","journal-title":"Alzheimers Dement"},{"issue":"23","key":"2151_CR64","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.3390\/cells12232726","volume":"12","author":"E Knezevic","year":"2023","unstructured":"Knezevic E, Nenic K, Milanovic V, Knezevic NN (2023) The role of cortisol in chronic Stress, neurodegenerative Diseases, and psychological disorders. Cells 12(23):2726","journal-title":"Cells"},{"issue":"1","key":"2151_CR56","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5056\/jnm18087","volume":"25","author":"K Kowalski","year":"2019","unstructured":"Kowalski K, Mulak A (2019) Brain-Gut-Microbiota axis in alzheimer\u2019s disease. J Neurogastroenterol Motil 25(1):48\u201360","journal-title":"J Neurogastroenterol Motil"},{"key":"2151_CR41","unstructured":"Kuhn J, Sharman T (2023) Cerebral Amyloid Angiopathy. StatPearls"},{"issue":"5","key":"2151_CR138","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2174\/1389450122666211118125233","volume":"23","author":"M Kumar","year":"2022","unstructured":"Kumar M, Bansal N (2022) A revisit to etiopathogenesis and therapeutic strategies in alzheimer\u2019s disease. Curr Drug Targets 23(5):486\u2013512","journal-title":"Curr Drug Targets"},{"issue":"3","key":"2151_CR4","first-page":"453","volume":"13","author":"M Kurkinen","year":"2023","unstructured":"Kurkinen M, Fu\u0142ek M, Fu\u0142ek K, Besz\u0142ej JA, Kurpas D, Leszek J (2023) The amyloid cascade hypothesis in alzheimer\u2019s disease. Should We Change our Thinking? Biomolecules 13(3):453","journal-title":"Should We Change our Thinking? Biomolecules"},{"key":"2151_CR141","doi-asserted-by":"crossref","unstructured":"Lang FM, Mo Y, Sabbagh M, Solomon P, Boada M, Jones RW et al (2021) Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer\u2019s disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET). Alzheimer\u2019s Dement (New York, N Y). ;7(1)","DOI":"10.1002\/trc2.12136"},{"issue":"9","key":"2151_CR149","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.2174\/0929867327666200312114223","volume":"28","author":"CSW Law","year":"2021","unstructured":"Law CSW, Yeong KY (2021) Repurposing antihypertensive drugs for the management of alzheimer\u2019s disease. Curr Med Chem 28(9):1716\u20131730","journal-title":"Curr Med Chem"},{"issue":"1","key":"2151_CR152","first-page":"144","volume":"3","author":"EH Lee","year":"2023","unstructured":"Lee EH, CY;, Yun C-Y;, Li TYW, Sia C-H, Thong EH, Lee ECY et al (2023) Aspirin Therapy, cognitive Impairment, and Dementia\u2014A review. Futur Pharmacol 2023 3(1):144\u2013161","journal-title":"Futur Pharmacol 2023"},{"issue":"1","key":"2151_CR177","first-page":"1","volume":"16","author":"Z Li","year":"2024","unstructured":"Li Z, Lin C, Cai X, Lv F, Yang W, Ji L (2024) Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials. Alzheimer\u2019s Res Ther 16(1):1\u201316","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"e1","key":"2151_CR170","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1136\/bmjspcare-2020-002242","volume":"14","author":"P Lindeza","year":"2024","unstructured":"Lindeza P, Rodrigues M, Costa J, Guerreiro M, Rosa MM (2024) Impact of dementia on informal care: a systematic review of family caregivers\u2019 perceptions. BMJ Support Palliat Care 14(e1):e38\u201349","journal-title":"BMJ Support Palliat Care"},{"key":"2151_CR121","doi-asserted-by":"publisher","first-page":"154594","DOI":"10.1016\/j.phymed.2022.154594","volume":"109","author":"P Liu","year":"2023","unstructured":"Liu P, Wang C, Chen W, Kang Y, Liu W, Qiu Z et al (2023) Inhibition of GluN2B pathway is involved in the neuroprotective effect of Silibinin on streptozotocin-induced alzheimer\u2019s disease models. Phytomedicine 109:154594","journal-title":"Phytomedicine"},{"issue":"9","key":"2151_CR53","doi-asserted-by":"publisher","first-page":"e30523","DOI":"10.1016\/j.heliyon.2024.e30523","volume":"10","author":"LC Liu","year":"2024","unstructured":"Liu LC, Liang JY, Liu YH, Liu B, Dong XH, Cai WH, Zhang N (2024) The Intersection of cerebral cholesterol metabolism and Alzheimer\u2019s disease: Mechanisms and therapeutic prospects. Heliyon 10(9):e30523","journal-title":"Heliyon"},{"key":"2151_CR28","doi-asserted-by":"publisher","first-page":"1449575","DOI":"10.3389\/fnagi.2024.1449575","volume":"16","author":"J Lu","year":"2024","unstructured":"Lu J, Li CJ, Wang J, Wang Y (2024) Neuropathology and neuroinflammation in alzheimer\u2019s disease via bidirectional lung\u2013brain axis. Front Aging Neurosci 16:1449575","journal-title":"Front Aging Neurosci"},{"key":"2151_CR88","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/B978-0-12-394816-8.00006-4","volume":"64","author":"K Ma","year":"2012","unstructured":"Ma K, Thomason LAM, McLaurin JA (2012) scyllo-Inositol, preclinical, and clinical data for alzheimer\u2019s disease. Adv Pharmacol 64:177\u2013212","journal-title":"Adv Pharmacol"},{"issue":"1","key":"2151_CR34","first-page":"1","volume":"12","author":"A MacHado","year":"2020","unstructured":"MacHado A, Ferreira D, Grothe MJ, Eyjolfsdottir H, Almqvist PM, Cavallin L et al (2020) The cholinergic system in subtypes of alzheimer\u2019s disease: an in vivo longitudinal MRI study. Alzheimer\u2019s Res Ther 12(1):1\u201311","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"2151_CR87","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fneur.2020.00614","volume":"11","author":"S Manzano","year":"2020","unstructured":"Manzano S, Ag\u00fcera L, Aguilar M, Olazar\u00e1n J (2020) A review on Tramiprosate (Homotaurine) in alzheimer\u2019s disease and other neurocognitive disorders. Front Neurol 11:614","journal-title":"Front Neurol"},{"issue":"10","key":"2151_CR173","first-page":"1934","volume":"40","author":"TB Marvasti","year":"2024","unstructured":"Marvasti TB, Gao Y, Murray KR, Hershman S, McIntosh C, Moayedi Y (2024) Unlocking tomorrow\u2019s health care: expanding the clinical scope of wearables by applying artificial intelligence. Can J Cardiol 40(10):1934\u20131945","journal-title":"Can J Cardiol"},{"issue":"6","key":"2151_CR115","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/13543784.2025.2522885","volume":"34","author":"RS McIntyre","year":"2025","unstructured":"McIntyre RS (2025) Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments for manic episodes, mixed features and cognitive deficits in bipolar disorder? Expert Opin Investig Drugs 34(6):519\u2013526","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"2151_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3390\/biom15050712","volume":"15","author":"A Mekala","year":"2025","unstructured":"Mekala A, Qiu H (2025) Interplay between vascular dysfunction and neurodegenerative pathology: new insights into molecular mechanisms and management. Biomolecules 15(5):712","journal-title":"Biomolecules"},{"issue":"18","key":"2151_CR82","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW et al (2021) Donanemab in early alzheimer\u2019s disease. N Engl J Med 384(18):1691\u20131704","journal-title":"N Engl J Med"},{"key":"2151_CR36","doi-asserted-by":"publisher","first-page":"617588","DOI":"10.3389\/fnagi.2021.617588","volume":"13","author":"A Misrani","year":"2021","unstructured":"Misrani A, Tabassum S, Yang L (2021) Mitochondrial dysfunction and oxidative stress in alzheimer\u2019s disease. Front Aging Neurosci 13:617588","journal-title":"Front Aging Neurosci"},{"key":"2151_CR174","doi-asserted-by":"publisher","first-page":"115522","DOI":"10.1016\/j.bcp.2023.115522","volume":"211","author":"AR Monteiro","year":"2023","unstructured":"Monteiro AR, Barbosa DJ, Remi\u00e3o F, Silva R (2023) Alzheimer\u2019s disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol 211:115522","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2151_CR51","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/cells14020140","volume":"14","author":"AD Mooradian","year":"2025","unstructured":"Mooradian AD, Haas MJ (2025) Role of thyroid hormone in neurodegenerative disorders of older people. Cells 14(2):140","journal-title":"Cells"},{"issue":"8","key":"2151_CR95","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1007\/s11011-023-01295-3","volume":"38","author":"RE Mostafa","year":"2023","unstructured":"Mostafa RE, Asaad GF (2023) Meclizine moderates lipopolysaccharide-induced neuroinflammation in mice through the regulation of AKT\/ NF-\u03ba\u03b2\/ERK\/JNK signaling pathway. Metab Brain Dis 38(8):2797\u20132806","journal-title":"Metab Brain Dis"},{"issue":"1","key":"2151_CR20","first-page":"43","volume":"15","author":"M Nasb","year":"2024","unstructured":"Nasb M, Tao W, Chen N (2024) Alzheimer\u2019s disease puzzle: delving into pathogenesis hypotheses. Aging Dis 15(1):43\u201373","journal-title":"Aging Dis"},{"issue":"1","key":"2151_CR108","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/nmt-2020-0052","volume":"11","author":"K Nguyen","year":"2021","unstructured":"Nguyen K, Hoffman H, Chakkamparambil B, Grossberg GT (2021) Evaluation of Rivastigmine in alzheimer\u2019s disease. Neurodegener Dis Manag 11(1):35\u201348","journal-title":"Neurodegener Dis Manag"},{"key":"2151_CR74","doi-asserted-by":"publisher","first-page":"1279740","DOI":"10.3389\/fnmol.2023.1279740","volume":"16","author":"G Nordvall","year":"2023","unstructured":"Nordvall G, Lundkvist J, Sandin J (2023) Gamma-secretase modulators: a promising route for the treatment of alzheimer\u2019s disease. Front Mol Neurosci 16:1279740","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"2151_CR114","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s10571-022-01274-9","volume":"43","author":"D Nuzzo","year":"2023","unstructured":"Nuzzo D, Frinchi M, Giardina C, Scordino M, Zuccarini M, De Simone C et al (2023) Neuroprotective and antioxidant role of Oxotremorine-M, a Non-selective muscarinic acetylcholine receptors Agonist, in a cellular model of alzheimer disease. Cell Mol Neurobiol 43(5):1941\u20131956","journal-title":"Cell Mol Neurobiol"},{"key":"2151_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","volume":"34","author":"RJ O\u2019Brien","year":"2011","unstructured":"O\u2019Brien RJ, Wong PC (2011a) Amyloid precursor protein processing and alzheimer\u2019s disease. Annu Rev Neurosci 34:185\u2013204","journal-title":"Annu Rev Neurosci"},{"key":"2151_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","volume":"34","author":"RJ O\u2019Brien","year":"2011","unstructured":"O\u2019Brien RJ, Wong PC (2011b) Amyloid precursor protein processing and alzheimer\u2019s disease. Annu Rev Neurosci 34:185","journal-title":"Annu Rev Neurosci"},{"issue":"10","key":"2151_CR101","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.3390\/cells10102790","volume":"10","author":"G Ogunmokun","year":"2021","unstructured":"Ogunmokun G, Dewanjee S, Chakraborty P, Valupadas C, Chaudhary A, Kolli V et al (2021) The potential role of cytokines and growth factors in the pathogenesis of alzheimer\u2019s disease. Cells 10(10):2790","journal-title":"Cells"},{"issue":"1","key":"2151_CR102","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12906-025-04769-2","volume":"25","author":"OB Ogunro","year":"2025","unstructured":"Ogunro OB, Karigidi ME, Gyebi GA, Turkistani A, Almehmadi AH (2025) Tangeretin offers neuroprotection against colchicine-induced memory impairment in Wistar rats by modulating the antioxidant milieu, inflammatory mediators and oxidative stress in the brain tissue. BMC Complement Med Ther 25(1):40","journal-title":"BMC Complement Med Ther"},{"issue":"5","key":"2151_CR150","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurjpc\/zwab208","volume":"29","author":"E Olmastroni","year":"2022","unstructured":"Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M et al (2022) Statin use and risk of dementia or alzheimer\u2019s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol 29(5):804\u2013814","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"2151_CR179","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ijms21030952","volume":"21","author":"K Ono","year":"2020","unstructured":"Ono K, Tsuji M (2020) Protofibrils of amyloid-\u03b2 are important targets of a disease-modifying approach for alzheimer\u2019s disease. Int J Mol Sci 21(3):952","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2151_CR178","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","volume":"31","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist S, Warmenhoven N, Anastasi F, Pilotto A, Janelidze S, Tideman P et al (2025) Plasma phospho-tau217 for alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform. Nat Med 31(6):2036\u20132043","journal-title":"Nat Med"},{"issue":"6","key":"2151_CR107","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/pharmaceutics14061117","volume":"14","author":"T Pardo-Moreno","year":"2022","unstructured":"Pardo-Moreno T, Gonz\u00e1lez-Acedo A, Rivas-Dom\u00ednguez A, Garc\u00eda-Morales V, Garc\u00eda-Cozar FJ, Ramos-Rodr\u00edguez JJ et al (2022) Therapeutic approach to alzheimer\u2019s disease: current treatments and new perspectives. Pharmaceutics 14(6):1117","journal-title":"Pharmaceutics"},{"issue":"10","key":"2151_CR157","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1080\/03007995.2021.1957807","volume":"37","author":"SH Park","year":"2021","unstructured":"Park SH, Lee JH, Shin J, Kim JS, Cha B, Lee S et al (2021) Cognitive function improvement after fecal microbiota transplantation in alzheimer\u2019s dementia patient: a case report. Curr Med Res Opin 37(10):1739\u20131744","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"2151_CR59","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.18103\/mra.v12i10.5825","volume":"12","author":"HH Park","year":"2024","unstructured":"Park HH, Armstrong MJ, Gorin FA, Lein PJ (2024) Air pollution as an environmental risk factor for alzheimer\u2019s disease and related dementias. Med Res Arch 12(10):5825","journal-title":"Med Res Arch"},{"issue":"10S","key":"2151_CR140","doi-asserted-by":"publisher","first-page":"S489","DOI":"10.14309\/01.ajg.0000952316.75192.6a","volume":"118","author":"P Patel","year":"2023","unstructured":"Patel P, Khataniar H, Loganathan P, Mohan B (2023) S669 safety and efficacy of highly selective 5-HT4 agonist (Velusetrag, Felcisetrag, Prucalopride) for Diabetic\/Idiopathic Gastroparesis\u2014Systematic review and Meta-Analysis of randomized controlled trials. Am J Gastroenterol 118(10S):S489\u2013S490","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2151_CR118","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1007\/s11010-025-05214-1","volume":"480","author":"M Pelczarski","year":"2025","unstructured":"Pelczarski M, Wolaniuk S, Zaborska M, Sadowski J, Sztangreciak-Lehun A, Bu\u0142dak RJ (2025) The role of \u03b1-tocopherol in the prevention and treatment of alzheimer\u2019s disease. Mol Cell Biochem 480(6):3385\u20133398","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"2151_CR77","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3233\/JAD-160275","volume":"53","author":"R Penninkilampi","year":"2016","unstructured":"Penninkilampi R, Brothers HM, Eslick GD (2016) Pharmacological agents targeting \u03b3-Secretase increase risk of cancer and cognitive decline in alzheimer\u2019s disease patients: A systematic review and Meta-Analysis. J Alzheimers Dis 53(4):1395\u20131404","journal-title":"J Alzheimers Dis"},{"key":"2151_CR62","doi-asserted-by":"publisher","first-page":"1489489","DOI":"10.3389\/fnut.2024.1489489","volume":"11","author":"P Picone","year":"2024","unstructured":"Picone P, Girgenti A, Buttacavoli M, Nuzzo D (2024) Enriching the mediterranean diet could nourish the brain more effectively. Front Nutr 11:1489489","journal-title":"Front Nutr"},{"issue":"3","key":"2151_CR176","doi-asserted-by":"publisher","first-page":"371","DOI":"10.14283\/jpad.2021.23","volume":"8","author":"AP Porsteinsson","year":"2021","unstructured":"Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I (2021) Diagnosis of early alzheimer\u2019s disease: clinical practice in 2021. J Prev Alzheimer\u2019s Dis 8(3):371\u2013386","journal-title":"J Prev Alzheimer\u2019s Dis"},{"issue":"1","key":"2151_CR134","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13063-024-08001-3","volume":"25","author":"N Possemis","year":"2024","unstructured":"Possemis N, Verhey F, Prickaerts J, Blokland A, Ramakers I (2024) A proof of concept phase II study with the PDE-4 inhibitor Roflumilast in patients with mild cognitive impairment or mild alzheimer\u2019s disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial. Trials 25(1):162","journal-title":"Trials"},{"issue":"15","key":"2151_CR104","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.3390\/nu17152557","volume":"17","author":"N Puranik","year":"2025","unstructured":"Puranik N, Kumari M, Tiwari S, Dhakal T, Song M (2025) Resveratrol as a therapeutic agent in alzheimer\u2019s disease: evidence from clinical studies. Nutrients 17(15):2557","journal-title":"Nutrients"},{"issue":"1","key":"2151_CR63","first-page":"1","volume":"2","author":"SM Ragsdale","year":"2025","unstructured":"Ragsdale SM, Radovich JM, Coiduras II, McCall WV, Grant SC, Lee C et al (2025) Dual orexin receptor antagonists as promising therapeutics for alzheimer\u2019s disease. Npj Biol Timing Sleep 2025 21 2(1):1\u201313","journal-title":"Npj Biol Timing Sleep 2025 21"},{"key":"2151_CR99","doi-asserted-by":"publisher","first-page":"e20240204","DOI":"10.1590\/1980-5764-dn-2024-0204","volume":"19","author":"S Rajanna","year":"2025","unstructured":"Rajanna S, Gundale PP, Mahadevaiah AD (2025) Advancements in the treatment of alzheimer\u2019s disease: a comprehensive review. Dement Neuropsychol 19:e20240204","journal-title":"Dement Neuropsychol"},{"key":"2151_CR175","first-page":"123","volume":"9","author":"J Rasmussen","year":"2019","unstructured":"Rasmussen J, Langerman H (2019) Alzheimer\u2019s Disease \u2013 Why we need early diagnosis. Degener Neurol Neuromuscul Dis 9:123","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"18","key":"2151_CR143","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1021\/acschemneuro.4c00304","volume":"15","author":"D Rivera-Illanes","year":"2024","unstructured":"Rivera-Illanes D, Recabarren-Gajardo G (2024) Classics in chemical neuroscience: muscimol. ACS Chem Neurosci 15(18):3257\u20133269","journal-title":"ACS Chem Neurosci"},{"issue":"19","key":"2151_CR98","doi-asserted-by":"publisher","first-page":"14175","DOI":"10.1021\/acs.jmedchem.1c00935","volume":"64","author":"FJR Rombouts","year":"2021","unstructured":"Rombouts FJR, Kusakabe KI, Alexander R, Austin N, Borghys H, De Cleyn M et al (2021) JNJ-67569762, A 2-Aminotetrahydropyridine-Based selective BACE1 inhibitor targeting the S3 pocket: from discovery to clinical candidate. J Med Chem 64(19):14175\u201314191","journal-title":"J Med Chem"},{"issue":"2","key":"2151_CR189","doi-asserted-by":"publisher","first-page":"e70076","DOI":"10.1002\/trc2.70076","volume":"11","author":"M Sabbagh","year":"2025","unstructured":"Sabbagh M, Boschini C, Cohen S, Fugger M, Jessen F, Dandanell S et al (2025a) Safety considerations of semaglutide in the potential treatment of alzheimer\u2019s disease: A pooled analysis of semaglutide in adults aged\u2009\u2265\u200965 years. Alzheimer\u2019s Dement Transl Res Clin Interv 11(2):e70076","journal-title":"Alzheimer\u2019s Dement Transl Res Clin Interv"},{"key":"2151_CR190","doi-asserted-by":"crossref","unstructured":"Sabbagh MN, Kennedy J, Majeed J, Decourt B (2025b) Alzheimer\u2019s disease: clinical trials to watch. Med. ;6(8)","DOI":"10.1016\/j.medj.2025.100771"},{"issue":"12","key":"2151_CR133","doi-asserted-by":"publisher","first-page":"e2344938","DOI":"10.1001\/jamanetworkopen.2023.44938","volume":"6","author":"S Saito","year":"2023","unstructured":"Saito S, Suzuki K, Ohtani R, Maki T, Kowa H, Tachibana H et al (2023) Efficacy and safety of cilostazol in mild cognitive impairment: A randomized clinical trial. JAMA Netw Open ;6(12):e2344938","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2151_CR185","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/ggi.70088","volume":"25","author":"T Sakurai","year":"2025","unstructured":"Sakurai T, Sugimoto T, Arai H (2025) Multidomain interventions for prevention of dementia: Achievements, challenges and future perspectives. Geriatr Gerontol Int 25(8):1015","journal-title":"Geriatr Gerontol Int"},{"issue":"18","key":"2151_CR93","doi-asserted-by":"publisher","first-page":"8992","DOI":"10.1080\/07391102.2022.2139760","volume":"41","author":"E Sarukhanyan","year":"2023","unstructured":"Sarukhanyan E, Dandekar T (2023) In Silico designed microtubule-stabilizer drugs against tauopathy in alzheimer\u2019s disease. J Biomol Struct Dyn 41(18):8992\u20139012","journal-title":"J Biomol Struct Dyn"},{"issue":"4","key":"2151_CR148","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1161\/ATVBAHA.120.311911","volume":"41","author":"S Scheffer","year":"2021","unstructured":"Scheffer S, Hermkens DMA, Van Der Weerd L, De Vries HE, Daemen MJAP (2021) Vascular hypothesis of alzheimer disease: topical review of mouse models. Arterioscler Thromb Vasc Biol 41(4):1265\u20131283","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"2151_CR57","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3390\/cells9081909","volume":"9","author":"I Schoultz","year":"2020","unstructured":"Schoultz I, Keita \u00c5V (2020) The intestinal barrier and current techniques for the assessment of gut permeability. Cells 9(8):1909","journal-title":"Cells"},{"issue":"6","key":"2151_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016a) The amyloid hypothesis of alzheimer\u2019s disease at 25 years. EMBO Mol Med 8(6):595\u2013608","journal-title":"EMBO Mol Med"},{"issue":"6","key":"2151_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016b) The amyloid hypothesis of alzheimer\u2019s disease at 25 years. EMBO Mol Med 8(6):595","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2151_CR132","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12868-023-00790-8","volume":"24","author":"M Shekarian","year":"2023","unstructured":"Shekarian M, Salehi I, Raoufi S, Asadbegi M, Kourosh-Arami M, Komaki A (2023) Neuroprotective effects of vinpocetine, as a phosphodiesterase 1 inhibitor, on long-term potentiation in a rat model of alzheimer\u2019s disease. BMC Neurosci 24(1):20","journal-title":"BMC Neurosci"},{"key":"2151_CR127","doi-asserted-by":"publisher","first-page":"113224","DOI":"10.1016\/j.biopha.2022.113224","volume":"152","author":"M Sheykhhasan","year":"2022","unstructured":"Sheykhhasan M, Amini R, Soleimani Asl S, Saidijam M, Hashemi SM, Najafi R (2022) Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adipose-derived stem cells in a rat model of alzheimer\u2019s disease. Biomed Pharmacother 152:113224","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2151_CR126","first-page":"573","volume":"10","author":"LJ Shinn","year":"2021","unstructured":"Shinn LJ, Lagalwar S (2021) Treating neurodegenerative disease with antioxidants: efficacy of the bioactive phenol Resveratrol and Mitochondrial-Targeted MitoQ and SkQ. Antioxid (Basel Switzerland) 10(4):573","journal-title":"Antioxid (Basel Switzerland)"},{"issue":"4","key":"2151_CR92","doi-asserted-by":"publisher","first-page":"688","DOI":"10.34172\/apb.2023.071","volume":"13","author":"SR Shri","year":"2023","unstructured":"Shri SR, Manandhar S, Nayak Y, Pai KSR (2023) Role of GSK-3\u03b2 inhibitors: new promises and opportunities for alzheimer\u2019s disease. Adv Pharm Bull 13(4):688\u2013700","journal-title":"Adv Pharm Bull"},{"issue":"1","key":"2151_CR86","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","volume":"11","author":"C Song","year":"2022","unstructured":"Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L et al (2022) Immunotherapy for alzheimer\u2019s disease: targeting \u03b2-amyloid and beyond. Transl Neurodegener 11(1):18","journal-title":"Transl Neurodegener"},{"issue":"3","key":"2151_CR73","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","volume":"78","author":"R Sperling","year":"2021","unstructured":"Sperling R, Henley D, Aisen PS, Raman R, Donohue MC, Ernstrom K et al (2021) Findings of Efficacy, Safety, and biomarker outcomes of atabecestat in preclinical alzheimer disease: A truncated randomized phase 2b\/3 clinical trial. JAMA Neurol 78(3):293\u2013301","journal-title":"JAMA Neurol"},{"issue":"S2","key":"2151_CR42","doi-asserted-by":"publisher","first-page":"e037027","DOI":"10.1002\/alz.037027","volume":"16","author":"GNH Sree","year":"2020","unstructured":"Sree GNH, Marisse LP, Vithal KM, Satish A, Rajalekshmi KS (2020) Genetic associations in alzheimer\u2019s disease: A systematic review and meta-analysis. Alzheimer\u2019s Dement 16(S2):e037027","journal-title":"Alzheimer\u2019s Dement"},{"issue":"s1","key":"2151_CR124","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.3233\/JAD-230760","volume":"101","author":"MJ Steinbach","year":"2024","unstructured":"Steinbach MJ, Denburg NL (2024) Melatonin in alzheimer\u2019s disease: literature review and therapeutic trials. J Alzheimers Dis 101(s1):S193\u2013204","journal-title":"J Alzheimers Dis"},{"key":"2151_CR109","doi-asserted-by":"crossref","unstructured":"Sundius T, Brand\u00e1n SA (2023) Structural, harmonic force field and vibrational studies of cholinesterase inhibitor Tacrine used for treatment of alzheimer\u2019s disease. Heliyon ;9(6)","DOI":"10.1016\/j.heliyon.2023.e17280"},{"issue":"1","key":"2151_CR75","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.celrep.2017.09.032","volume":"21","author":"S Tagami","year":"2017","unstructured":"Tagami S, Yanagida K, Kodama TS, Takami M, Mizuta N, Oyama H et al (2017) Semagacestat is a Pseudo-Inhibitor of \u03b3-Secretase. Cell Rep 21(1):259\u2013273","journal-title":"Cell Rep"},{"issue":"3","key":"2151_CR130","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ibra.12098","volume":"9","author":"BC Tang","year":"2023","unstructured":"Tang BC, Wang YT, Ren J (2023) Basic information about memantine and its treatment of alzheimer\u2019s disease and other clinical applications. Ibrain 9(3):340\u2013348","journal-title":"Ibrain"},{"issue":"11","key":"2151_CR156","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s00210-023-02554-x","volume":"396","author":"A Thakkar","year":"2023","unstructured":"Thakkar A, Vora A, Kaur G, Akhtar J (2023) Dysbiosis and alzheimer\u2019s disease: role of probiotics, prebiotics and synbiotics. Naunyn Schmiedebergs Arch Pharmacol 396(11):2911\u20132923","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"2151_CR151","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bph.16032","volume":"181","author":"R Toribio-Fernandez","year":"2024","unstructured":"Toribio-Fernandez R, Ceron C, Trist\u00e3o-Pereira C, Fernandez-Nueda I, Perez-Castillo A, Fernandez-Ferro J et al (2024) Oral anticoagulants: A plausible new treatment for alzheimer\u2019s disease? Br J Pharmacol 181(6):760\u2013776","journal-title":"Br J Pharmacol"},{"key":"2151_CR31","doi-asserted-by":"publisher","first-page":"907804","DOI":"10.3389\/fimmu.2022.907804","volume":"13","author":"VTA Tran","year":"2022","unstructured":"Tran VTA, Lee LP, Cho H (2022) Neuroinflammation in neurodegeneration via microbial infections. Front Immunol 13:907804","journal-title":"Front Immunol"},{"issue":"1","key":"2151_CR22","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.tjpad.2024.100013","volume":"12","author":"Z Valiukas","year":"2025","unstructured":"Valiukas Z, Tangalakis K, Apostolopoulos V, Feehan J (2025) Microglial activation States and their implications for alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis 12(1):100013","journal-title":"J Prev Alzheimer\u2019s Dis"},{"issue":"3","key":"2151_CR80","first-page":"142","volume":"22","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early alzheimer\u2019s disease. N Engl J Med 22(3):142\u2013143","journal-title":"N Engl J Med"},{"issue":"12","key":"2151_CR81","doi-asserted-by":"publisher","first-page":"e70905","DOI":"10.1002\/alz.70905","volume":"21","author":"CH van Dyck","year":"2025","unstructured":"van Dyck CH, Sperling R, Johnson K, Dhadda S, Kanekiyo M, Li D et al (2025) Long-term safety and efficacy of Lecanemab in early alzheimer\u2019s disease: results from the clarity AD open-label extension study. Alzheimers Dement 21(12):e70905","journal-title":"Alzheimers Dement"},{"key":"2151_CR85","doi-asserted-by":"crossref","unstructured":"Vandenberghe R, Riviere ME, Caputo A, Sovago J, Maguire RP, Farlow M et al (2016) Active A\u03b2 immunotherapy CAD106 in alzheimer\u2019s disease: A phase 2b study, vol 3. Alzheimer\u2019s Dement, pp 10\u201322. (New York, N Y)1","DOI":"10.1016\/j.trci.2016.12.003"},{"issue":"8","key":"2151_CR161","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/cells11081367","volume":"11","author":"A Varesi","year":"2022","unstructured":"Varesi A, Carrara A, Pires VG, Floris V, Pierella E, Savioli G et al (2022) Blood-Based biomarkers for alzheimer\u2019s disease diagnosis and progression: an overview. Cells 11(8):1367","journal-title":"Cells"},{"issue":"2","key":"2151_CR84","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/156720509787602852","volume":"6","author":"B Vellas","year":"2009","unstructured":"Vellas B, Black R, Thal L, Fox N, Daniels M, McLennan G et al (2009) Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 6(2):144\u2013151","journal-title":"Curr Alzheimer Res"},{"issue":"8","key":"2151_CR112","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/jphp.12919","volume":"70","author":"S Verma","year":"2018","unstructured":"Verma S, Kumar A, Tripathi T, Kumar A (2018) Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in alzheimer\u2019s disease therapy. J Pharm Pharmacol 70(8):985\u2013993","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"2151_CR169","doi-asserted-by":"publisher","first-page":"100028","DOI":"10.1016\/j.tjpad.2024.100028","volume":"12","author":"AN Vidyanti","year":"2025","unstructured":"Vidyanti AN, Rahmawati F, Rahman RH, Prodjohardjono A, Gofir A (2025) Lifestyle interventions for dementia risk reduction: A review on the role of physical activity and diet in Western and Asian countries. J Prev Alzheimer\u2019s Dis 12(2):100028","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"2151_CR146","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/7854_2021_231","volume":"52","author":"S Vlachou","year":"2022","unstructured":"Vlachou S (2022) GABAB receptors and cognitive processing in health and disease. Curr Top Behav Neurosci 52:291\u2013329","journal-title":"Curr Top Behav Neurosci"},{"key":"2151_CR47","doi-asserted-by":"publisher","first-page":"646901","DOI":"10.3389\/fnagi.2021.646901","volume":"13","author":"D Vogrinc","year":"2021","unstructured":"Vogrinc D, Gori\u010dar K, Dol\u017ean V (2021) Genetic variability in molecular pathways implicated in alzheimer\u2019s disease: A comprehensive review. Front Aging Neurosci 13:646901","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"2151_CR66","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrn.2016.13","volume":"17","author":"DM Walsh","year":"2016","unstructured":"Walsh DM, Selkoe DJ (2016) A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci 17(4):251","journal-title":"Nat Rev Neurosci"},{"key":"2151_CR27","doi-asserted-by":"publisher","first-page":"1117172","DOI":"10.3389\/fimmu.2023.1117172","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang C, Zong S, Cui X, Wang X, Wu S, Wang L et al (2023) The effects of microglia-associated neuroinflammation on alzheimer\u2019s disease. Front Immunol 14:1117172","journal-title":"Front Immunol"},{"issue":"2","key":"2151_CR11","first-page":"1","volume":"4","author":"S Weggen","year":"2012","unstructured":"Weggen S, Beher D (2012) Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 4(2):1\u201314","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"9","key":"2151_CR155","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.3390\/ijms23094862","volume":"23","author":"B Wiatrak","year":"2022","unstructured":"Wiatrak B, Balon K, Jawie\u0144 P, Bednarz D, J\u0119\u015bkowiak I, Szel\u0105g A (2022) The role of the Microbiota-Gut-Brain axis in the development of alzheimer\u2019s disease. Int J Mol Sci 23(9):4862","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2151_CR171","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1002\/alz.13104","volume":"19","author":"LAK Wiese","year":"2023","unstructured":"Wiese LAK, Gibson A, Guest MA, Nelson AR, Weaver R, Gupta A et al (2023) Global rural health disparities in alzheimer\u2019s disease and related dementias: state of the science. Alzheimers Dement 19(9):4204","journal-title":"Alzheimers Dement"},{"issue":"Suppl 8","key":"2151_CR187","first-page":"e095413","volume":"20","author":"JD Williamson","year":"2025","unstructured":"Williamson JD (2025) Primary results from SPRINT MIND 2020. Alzheimer\u2019s Dement 20(Suppl 8):e095413","journal-title":"Alzheimer\u2019s Dement"},{"issue":"5","key":"2151_CR163","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.3390\/ijms24054367","volume":"24","author":"K Wojtunik-Kulesza","year":"2023","unstructured":"Wojtunik-Kulesza K, Rudkowska M, Orze\u0142-Sajd\u0142owska A (2023) Aducanumab\u2014Hope or disappointment for alzheimer\u2019s disease. Int J Mol Sci 24(5):4367","journal-title":"Int J Mol Sci"},{"key":"2151_CR24","doi-asserted-by":"publisher","first-page":"1161850","DOI":"10.3389\/fphar.2023.1161850","volume":"14","author":"M Wong-Guerra","year":"2023","unstructured":"Wong-Guerra M, Calfio C, Maccioni RB, Rojo LE (2023a) Revisiting the neuroinflammation hypothesis in alzheimer\u2019s disease: a focus on the druggability of current targets. Front Pharmacol 14:1161850","journal-title":"Front Pharmacol"},{"key":"2151_CR105","doi-asserted-by":"publisher","first-page":"1161850","DOI":"10.3389\/fphar.2023.1161850","volume":"14","author":"M Wong-Guerra","year":"2023","unstructured":"Wong-Guerra M, Calfio C, Maccioni RB, Rojo LE (2023b) Revisiting the neuroinflammation hypothesis in alzheimer\u2019s disease: a focus on the druggability of current targets. Front Pharmacol 14:1161850","journal-title":"Front Pharmacol"},{"issue":"6","key":"2151_CR70","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.14336\/AD.2022.0412","volume":"13","author":"T Wu","year":"2022","unstructured":"Wu T, Lin D, Cheng Y, Jiang S, Riaz MW, Fu N et al (2022) Amyloid cascade hypothesis for the treatment of alzheimer\u2019s disease: progress and challenges. Aging Dis 13(6):1745","journal-title":"Aging Dis"},{"issue":"3","key":"2151_CR125","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3390\/cells11030479","volume":"11","author":"L Xie","year":"2022","unstructured":"Xie L, Zhu Q, Lu J (2022) Can we use Ginkgo Biloba extract to treat alzheimer\u2019s disease? Lessons from preclinical and clinical studies. Cells 11(3):479","journal-title":"Cells"},{"key":"2151_CR159","doi-asserted-by":"publisher","first-page":"925991","DOI":"10.3389\/fnins.2022.925991","volume":"16","author":"B Xue","year":"2022","unstructured":"Xue B, Waseem SMA, Zhu Z, Alshahrani MA, Nazam N, Anjum F et al (2022) Brain-Derived neurotrophic factor: A connecting link between Nutrition, Lifestyle, and alzheimer\u2019s disease. Front Neurosci 16:925991","journal-title":"Front Neurosci"},{"issue":"7","key":"2151_CR19","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.4103\/1673-5374.385847","volume":"19","author":"J Ye","year":"2023","unstructured":"Ye J, Wan H, Chen S, Liu GP (2023a) Targeting Tau in alzheimer\u2019s disease: from mechanisms to clinical therapy. Neural Regen Res 19(7):1489","journal-title":"Neural Regen Res"},{"key":"2151_CR61","doi-asserted-by":"publisher","first-page":"105286","DOI":"10.1016\/j.neubiorev.2023.105286","volume":"152","author":"KX Ye","year":"2023","unstructured":"Ye KX, Sun L, Wang L, Khoo ALY, Lim KX, Lu G et al (2023b) The role of lifestyle factors in cognitive health and dementia in oldest-old: A systematic review. Neurosci Biobehav Rev 152:105286","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"2151_CR60","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1567205012666150204121719","volume":"12","author":"M Yegambaram","year":"2015","unstructured":"Yegambaram M, Manivannan B, Beach T, Halden R (2015) Role of environmental contaminants in the etiology of alzheimer\u2019s disease: A review. Curr Alzheimer Res 12(2):116\u2013146","journal-title":"Curr Alzheimer Res"},{"issue":"12","key":"2151_CR119","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.3390\/molecules27123737","volume":"27","author":"YMM Yelanchezian","year":"2022","unstructured":"Yelanchezian YMM, Waldvogel HJ, Faull RLM, Kwakowsky A (2022) Neuroprotective effect of caffeine in alzheimer\u2019s disease. Molecules 27(12):3737","journal-title":"Molecules"},{"issue":"6","key":"2151_CR54","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/febs.16344","volume":"290","author":"F Yin","year":"2022","unstructured":"Yin F (2022) Lipid metabolism and alzheimer\u2019s disease: clinical evidence, mechanistic link and therapeutic promise. FEBS J 290(6):1420","journal-title":"FEBS J"},{"issue":"1","key":"2151_CR162","first-page":"1","volume":"19","author":"X Zeng","year":"2024","unstructured":"Zeng X, Chen Y, Sehrawat A, Lee J, Lafferty TK, Kofler J et al (2024) Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting. Mol Neurodegener 2024 191 19(1):1\u201322","journal-title":"Mol Neurodegener 2024 191"},{"issue":"748","key":"2151_CR100","doi-asserted-by":"publisher","first-page":"eabk3411","DOI":"10.1126\/scisignal.abk3411","volume":"15","author":"ZW Zhang","year":"2022","unstructured":"Zhang ZW, Tu H, Jiang M, Vanan S, Chia SY, Jang SE et al (2022) The APP intracellular domain promotes LRRK2 expression to enable feed-forward neurodegenerative mechanisms in parkinson\u2019s disease. Sci Signal 15(748):eabk3411","journal-title":"Sci Signal"},{"key":"2151_CR135","doi-asserted-by":"publisher","first-page":"114798","DOI":"10.1016\/j.bbr.2023.114798","volume":"459","author":"H Zhao","year":"2024","unstructured":"Zhao H, Blokland A, Prickaerts J, Havekes R, Heckman PRA (2024) Treatment with the selective PDE4B inhibitor A-33 or PDE4D inhibitor Zatolmilast prevents sleep deprivation-induced deficits in Spatial pattern separation. Behav Brain Res 459:114798","journal-title":"Behav Brain Res"},{"issue":"0 1","key":"2151_CR37","first-page":"S253","volume":"33","author":"X Zhu","year":"2013","unstructured":"Zhu X, Perry G, Smitha MA, Wang X (2013) Abnormal mitochondrial dynamics in the pathogenesis of alzheimer\u2019s disease. J Alzheimers Dis 33(0 1):S253","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"2151_CR30","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.neurobiolaging.2015.02.019","volume":"36","author":"C Zhu","year":"2015","unstructured":"Zhu C, Herrmann US, Li B, Abakumova I, Moos R, Schwarz P et al (2015) Triggering receptor expressed on myeloid cells-2 is involved in prion-induced microglial activation but does not contribute to prion pathogenesis in mouse brains. Neurobiol Aging 36(5):1994\u20132003","journal-title":"Neurobiol Aging"},{"key":"2151_CR72","doi-asserted-by":"crossref","unstructured":"Zimmer JA, Shcherbinin S, Devous MD, Bragg SM, Selzler KJ, Wessels AM et al (2021) Lanabecestat: neuroimaging results in early symptomatic alzheimer\u2019s disease, vol 7. Alzheimer\u2019s Dement. (New York, N Y)1","DOI":"10.1002\/trc2.12123"},{"issue":"1","key":"2151_CR111","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40520-023-02675-6","volume":"36","author":"G Zuliani","year":"2024","unstructured":"Zuliani G, Zuin M, Romagnoli T, Polastri M, Cervellati C, Brombo G (2024) Acetyl-cholinesterase-inhibitors reconsidered. A narrative review of post-marketing studies on alzheimer\u2019s disease. Aging Clin Exp Res 36(1):23","journal-title":"Aging Clin Exp Res"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02151-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02151-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02151-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:41:11Z","timestamp":1781642471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02151-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":187,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02151-3","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal and human rights"}}]}}